Dr Reddys Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories has allotted 9,165 equity shares under ESOS on 09 December 2025.

Powered by Capital Market - Live News

Eftilagimod alfa is a novel immunotherapy with the potential to set a new standard of care in combination with anti-PD- (L)1 and chemotherapy as first-line therapy for non-small cell lung cancer. Eftilagimod Alfa?s broad potential extends to other major cancers across multiple stages of disease.

Under the terms, Immutep to receive upfront payment of $20 million (around AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestones payments of up to $349.5 million approximately AUD 528.4 million), plus double-digit royalties on commercial sales.

Under the terms of the agreement, Immutep grants Dr. Reddy?s an exclusive license, with the right to grant sublicense to develop, register and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The company aims to leverage its scientific capabilities and extensive market reach to drive the development and commercialization of the cancer therapy across multiple global markets.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company?s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter shed 0.76% to Rs 1,265.30 on the BSE.

Powered by Capital Market - Live News

Dr Reddys Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 1258.9, up 0.01% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.15% on the day, quoting at 26164.95. The Sensex is at 85592.35, down 0.13%. Dr Reddys Laboratories Ltd has added around 5.26% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.94% in last one month and is currently quoting at 22998.3, down 0.52% on the day. The volume in the stock stood at 9.23 lakh shares today, compared to the daily average of 16.06 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1263.2, down 0.14% on the day. Dr Reddys Laboratories Ltd is up 3.04% in last one year as compared to a 7.78% gain in NIFTY and a 1.9% gain in the Nifty Pharma index.

The PE of the stock is 19.45 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

AVT03 is a human monoclonal IgG2 antibody and biosimilar candidate to Prolia and Xgeva, which are both denosumab but in different presentations.

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid.

Xgeva is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

In May 2024, Dr. Reddy?s and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy?s is responsible for registration and commercialization in applicable markets, including the U.S. and Europe.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company?s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

Powered by Capital Market - Live News